TTC37 inhibitors are a class of chemical compounds that specifically target and inhibit the function of the Tetratricopeptide Repeat Domain 37 (TTC37) protein. TTC37 is involved in various cellular processes, particularly in RNA metabolism and protein-protein interactions. The protein contains multiple tetratricopeptide repeat (TPR) motifs, which are known to mediate protein-protein interactions that regulate several aspects of cellular function. TTC37 is a component of the Ski complex, which is involved in the exosome-mediated degradation of RNA, particularly in controlling the stability and turnover of messenger RNA (mRNA). By regulating RNA processing and degradation, TTC37 contributes to maintaining proper RNA levels within cells, influencing gene expression and cellular responses to changing conditions.
Inhibitors of TTC37 are typically designed to interfere with the protein's ability to form complexes with other proteins in the Ski complex or disrupt its role in RNA degradation. These compounds may bind to the TPR motifs or other functional domains essential for TTC37's interaction with its partners. By inhibiting TTC37, researchers can observe changes in RNA stability and degradation, providing insights into the regulatory mechanisms of RNA metabolism. Studying the effects of TTC37 inhibition also allows for a better understanding of its broader role in maintaining cellular homeostasis, as the Ski complex plays a key role in ensuring proper RNA processing. Through the use of TTC37 inhibitors, researchers can explore how this protein influences RNA decay, gene expression regulation, and the intricate balance of protein interactions within cells that depend on precise RNA control.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
May inhibit protein synthesis, potentially reducing TTC37 expression indirectly through global translational inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Could inhibit proteasome activity, possibly affecting TTC37 degradation and turnover. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Might affect lysosomal function, potentially influencing TTC37 degradation. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
May interfere with nucleotide synthesis, possibly affecting TTC37 mRNA synthesis and stability. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Could bind to DNA, inhibiting transcription and potentially reducing TTC37 mRNA synthesis. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
As a proteasome inhibitor, it might impact the degradation and turnover of TTC37. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Might inhibit mTOR pathway, potentially influencing TTC37 protein synthesis. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Could crosslink DNA, potentially affecting transcription and the expression of TTC37. | ||||||
Emetine | 483-18-1 | sc-470668 sc-470668A sc-470668B sc-470668C | 1 mg 10 mg 50 mg 100 mg | $440.00 $900.00 $1400.00 $2502.00 | ||
May inhibit protein synthesis, possibly affecting the expression levels of TTC37. | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | $42.00 $214.00 $832.00 $66.00 | 394 | |
Might cause premature chain termination during translation, affecting TTC37 protein synthesis. | ||||||